Stockscreener 앱 받기
767.85
0.99%
-7.68
시장 영업 전:
763.61
-4.24
-0.55%
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
DDD Partners LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline - GlobeNewswire Inc.
Aug Final Week: Does Regeneron Pharmaceuticals Inc have pricing power2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
OFI Invest Asset Management Buys Regeneron Pharmaceuticals Shares - National Today
OFI Invest Asset Management Buys Shares of 31,265 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC - MarketBeat
Regeneron (REGN) Faces $102M Charge Impacting Q1 2026 Earnings - GuruFocus
Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Analyst Lowers Price Target for REGN, Maintains Outperform Ratin - GuruFocus
Sanford C. Bernstein Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene - Barchart.com
Bernstein SocGen lowers Regeneron stock price target on revenue mix shift - Investing.com
Regeneron Pharmaceuticals, Inc. Form 8-K Filing Details for April 8, 2026 – Company Info, Stock, and Compliance 2324 - Minichart
Regeneron expects $102 million IPR&D charge to impact Q1 2026 earnings - Investing.com Australia
Raymond James reiterates Outperform on Regeneron stock on Eylea HD growth - Investing.com
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com
Avoiding Lag: Real-Time Signals in (REGN) Movement - Stock Traders Daily
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart.com
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $765, Maintains Sector Perform Rating - Moomoo
Monoclonal Antibody Therapeutics (Mabs) Market (2026-2033) | - openPR.com
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals - simplywall.st
Regeneron And TriNetX Partner To Expand Global Genomic And EHR Linked Data Platform - BioPharma APAC
Surprises Report: What are the future prospects of Regeneron Pharmaceuticals IncWeekly Market Outlook & Smart Swing Trading Techniques - baoquankhu1.vn
Targets Report: Is Regeneron Pharmaceuticals Inc gaining market shareQuarterly Earnings Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval - finance.yahoo.com
FDA approves expanded EYLEA HD dosing intervals - Eyes On Eyecare
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy - Yahoo Finance
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd - MarketBeat
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition - simplywall.st
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN
REGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regeneron Pharmaceuticals Inc (REGN) SEC filings - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists - finance.yahoo.com
Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc - GuruFocus
Regeneron (REGN) director Ryan sells $77,727 in stock By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals Inc (RGO.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron (REGN) director Ryan sells $77,727 in stock - Investing.com
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Best Pharmaceutical Stocks To Follow TodayApril 3rd - MarketBeat
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Australia
Regeneron Secures Two FDA Approvals in One Day: Does the Math Support an Above $1,200 Target? - TIKR.com
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation - FinancialContent
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In JapanLearn Why - simplywall.st
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow - BioSpace
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings - National Today
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - BioSpace
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD - VisionMonday.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com - Investing.com Australia
Regeneron partners with TriNetX for health data access - Investing.com
1.97%
1.82%
자본화:
|
볼륨(24시간):